Pfizer (NYSE:PFE) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE) in a research note published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $45.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Pfizer’s FY2024 earnings at $2.18 EPS.

Other equities analysts have also recently issued research reports about the stock. Argus cut shares of Pfizer from a buy rating to a hold rating in a research note on Friday, March 22nd. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an equal weight rating in a research note on Thursday, May 2nd. Finally, BMO Capital Markets restated an outperform rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of Hold and a consensus price target of $35.69.

Pfizer Stock Performance

Shares of PFE stock opened at $28.92 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average price of $28.25 and a 200-day moving average price of $27.72. Pfizer has a 52 week low of $25.20 and a 52 week high of $37.80. The firm has a market capitalization of $163.88 billion, a PE ratio of -481.92, a P/E/G ratio of 1.12 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the previous year, the business earned $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Neo Ivy Capital Management purchased a new stake in Pfizer during the third quarter valued at $641,000. Fortis Group Advisors LLC bought a new position in shares of Pfizer in the 3rd quarter valued at about $116,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Hudson Bay Capital Management LP increased its stake in Pfizer by 4,405.2% during the third quarter. Hudson Bay Capital Management LP now owns 2,595,000 shares of the biopharmaceutical company’s stock worth $86,076,000 after acquiring an additional 2,537,400 shares during the last quarter. Finally, Dagco Inc. raised its position in Pfizer by 54.5% during the third quarter. Dagco Inc. now owns 11,535 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 4,068 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.